Skip to main content
. 2017 Aug 21;20(12):979–987. doi: 10.1093/ijnp/pyx074

Figure 3.

Figure 3.

(A) Effect of tolcapone on middle latency peak amplitude across 10 midline centroids in low- vs high-baseline 5 choice-continuous performance test (5C-CPT) performers. *Significant drug x centroid x baseline performance interaction. (B) Waveform of tolcapone’s effect on P200 amplitude at centroid 1 in low vs high performers during nontarget trials. *Significant main effect of drug.